Wockhardt's stock jumped 20% to 780 rupees after its experimental antibiotic, Zaynich, successfully treated a US cancer patient with a chronic thigh infection caused by highly resistant bacteria.
The patient, who had been hospitalized for nearly nine months and had tried various antibiotics, showed significant improvement after four weeks of treatment with Zaynich.
Also read/watch - Zomato faces ₹9.45 crore GST demand from Karnataka tax authorities
The infection healed, allowing the patient to resume chemotherapy. This marks the first use of Zaynich in the US for such an infection.
Wockhardt is a global pharmaceutical company specializing in developing antibiotics to combat superbugs. It has six antibiotic programs designated by the USFDA as Qualified Infectious Disease Products.
With a significant research team and an international presence, Wockhardt develops and manufactures drugs globally.